180 related articles for article (PubMed ID: 19748422)
1. Exposure-response analyses of tigecycline tolerability in healthy subjects.
Passarell J; Ludwig E; Liolios K; Meagher AK; Grasela TH; Babinchak T; Ellis-Grosse EJ
Diagn Microbiol Infect Dis; 2009 Oct; 65(2):123-9. PubMed ID: 19748422
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects.
Muralidharan G; Micalizzi M; Speth J; Raible D; Troy S
Antimicrob Agents Chemother; 2005 Jan; 49(1):220-9. PubMed ID: 15616299
[TBL] [Abstract][Full Text] [Related]
3. Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline.
Conte JE; Golden JA; Kelly MG; Zurlinden E
Int J Antimicrob Agents; 2005 Jun; 25(6):523-9. PubMed ID: 15885987
[TBL] [Abstract][Full Text] [Related]
4. Metabolism, excretion, and pharmacokinetics of [14C]tigecycline, a first-in-class glycylcycline antibiotic, after intravenous infusion to healthy male subjects.
Hoffmann M; DeMaio W; Jordan RA; Talaat R; Harper D; Speth J; Scatina J
Drug Metab Dispos; 2007 Sep; 35(9):1543-53. PubMed ID: 17537869
[TBL] [Abstract][Full Text] [Related]
5. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose.
Rodvold KA; Gotfried MH; Cwik M; Korth-Bradley JM; Dukart G; Ellis-Grosse EJ
J Antimicrob Chemother; 2006 Dec; 58(6):1221-9. PubMed ID: 17012300
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and safety of a single intravenous dose of the antibiotic tigecycline in patients with cirrhosis.
Korth-Bradley JM; Baird-Bellaire SJ; Patat AA; Troy SM; Böhmer GM; Gleiter CH; Buecheler R; Morgan MY
J Clin Pharmacol; 2011 Jan; 51(1):93-101. PubMed ID: 20308689
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin.
Bergallo C; Jasovich A; Teglia O; Oliva ME; Lentnek A; de Wouters L; Zlocowski JC; Dukart G; Cooper A; Mallick R;
Diagn Microbiol Infect Dis; 2009 Jan; 63(1):52-61. PubMed ID: 18990531
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of a potential tigecycline-warfarin drug interaction.
Zimmerman JJ; Raible DG; Harper DM; Matschke K; Speth JL
Pharmacotherapy; 2008 Jul; 28(7):895-905. PubMed ID: 18576904
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamic evaluation of tigecycline against Acinetobacter baumannii in a murine pneumonia model.
Koomanachai P; Kim A; Nicolau DP
J Antimicrob Chemother; 2009 May; 63(5):982-7. PubMed ID: 19279050
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics of tigecycline in healthy volunteers.
Van Wart SA; Cirincione BB; Ludwig EA; Meagher AK; Korth-Bradley JM; Owen JS
J Clin Pharmacol; 2007 Jun; 47(6):727-37. PubMed ID: 17519399
[TBL] [Abstract][Full Text] [Related]
11. Absence of an interaction between tigecycline and digoxin in healthy men.
Zimmerman JJ; Harper DM; Matschke K; Speth JL; Raible DG; Fruncillo RJ
Pharmacotherapy; 2007 Jun; 27(6):835-44. PubMed ID: 17542766
[TBL] [Abstract][Full Text] [Related]
12. Serum and urine pharmacokinetics of tigecycline in obese class III and normal weight adults.
Pai MP
J Antimicrob Chemother; 2014 Jan; 69(1):190-9. PubMed ID: 23883872
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and safety profile of tigecycline in children aged 8 to 11 years with selected serious infections: a multicenter, open-label, ascending-dose study.
Purdy J; Jouve S; Yan JL; Balter I; Dartois N; Cooper CA; Korth-Bradley J
Clin Ther; 2012 Feb; 34(2):496-507.e1. PubMed ID: 22249106
[TBL] [Abstract][Full Text] [Related]
14. Tigecycline-induced pancreatitis.
Lipshitz J; Kruh J; Cheung P; Cassagnol M
J Clin Gastroenterol; 2009 Jan; 43(1):93. PubMed ID: 18769361
[No Abstract] [Full Text] [Related]
15. Pharmacokinetics, pharmacodynamics, safety and tolerability of tigecycline.
Rello J
J Chemother; 2005 Aug; 17 Suppl 1():12-22. PubMed ID: 16285354
[TBL] [Abstract][Full Text] [Related]
16. Use of a clinically derived exposure-response relationship to evaluate potential tigecycline-Enterobacteriaceae susceptibility breakpoints.
Ambrose PG; Meagher AK; Passarell JA; Van Wart SA; Cirincione BB; Rubino CM; Korth-Bradley JM; Babinchak T; Ellis-Grosse E
Diagn Microbiol Infect Dis; 2009 Jan; 63(1):38-42. PubMed ID: 19073300
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics of tigecycline in patients with complicated intra-abdominal or skin and skin structure infections.
Van Wart SA; Owen JS; Ludwig EA; Meagher AK; Korth-Bradley JM; Cirincione BB
Antimicrob Agents Chemother; 2006 Nov; 50(11):3701-7. PubMed ID: 16940069
[TBL] [Abstract][Full Text] [Related]
18. The pharmacokinetic and pharmacodynamic profile of tigecycline.
Meagher AK; Ambrose PG; Grasela TH; Ellis-Grosse EJ
Clin Infect Dis; 2005 Sep; 41 Suppl 5():S333-40. PubMed ID: 16080071
[TBL] [Abstract][Full Text] [Related]
19. Phase 3 study comparing tigecycline and ertapenem in patients with diabetic foot infections with and without osteomyelitis.
Lauf L; Ozsvár Z; Mitha I; Regöly-Mérei J; Embil JM; Cooper A; Sabol MB; Castaing N; Dartois N; Yan J; Dukart G; Maroko R
Diagn Microbiol Infect Dis; 2014 Apr; 78(4):469-80. PubMed ID: 24439136
[TBL] [Abstract][Full Text] [Related]
20. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data.
Babinchak T; Ellis-Grosse E; Dartois N; Rose GM; Loh E; ;
Clin Infect Dis; 2005 Sep; 41 Suppl 5():S354-67. PubMed ID: 16080073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
